Motley Fool  Mar 6  Comment 
Several of the most interesting drugs in development belong to Bellicum and bluebird bio, but which is the better stock pick right now?
Motley Fool  Feb 23  Comment 
Revenue and earnings aren't particularly important for the biotech at this stage.
Motley Fool  Feb 9  Comment 
Optimism soared after management updated investors on the progress it's making on its clinical-stage gene therapy pipeline.
Benzinga  Feb 6  Comment 
bluebird bio Inc (NASDAQ: BLUE) shares are trading lower by $2.00 at $76.65 in Monday's session. Its four-day rally from its January 31 low ($67.10) to as high as $78.80 in Friday's session before closing at $78.65 has been interrupted by a...
Benzinga  Jan 11  Comment 
On Wednesday, the Vetr crowd upgraded their rating for bluebird bio Inc (NASDAQ: BLUE) , from 2.5 Stars (Sell) issued two days ago, to 3.5 Stars (Buy). Crowd sentiment for the stock is generally cautious, with 66 percent of Vetr user ratings...
Motley Fool  Dec 9  Comment 
Will bluebird bio or Kite Pharma be the bigger winner in the CAR-T race?
Motley Fool  Dec 7  Comment 
A dilutive stock offering and comments from President-elect Donald Trump had the biotech's shares trading lower.
Motley Fool  Dec 3  Comment 
Following Donald Trump's election and ahead of the release of early-stage data for its multiple myeloma drug bb2121, investor optimism soared.
Motley Fool  Dec 2  Comment 
The exciting race to develop the first CAR-T therapy recently took some unexpected twists for Juno Therapeutics, bluebird bio, and Kite Pharma.
Motley Fool  Dec 1  Comment 
bluebird bio has released intriguing phase 1 trial data for its novel BCMA targeting CAR-T therapy for multiple myeloma.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki